Compare

Moderna/$MRNA

1D1W1M3M6MYTD1Y5YMAX

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Health
Primary listing
NASDAQ
Employees
4,700

Moderna Metrics

BasicAdvanced
$79B
-
-$7.03
1.17
-

What the Analysts think about Moderna

Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Analyst projections of the future price of Moderna stock.

Bulls say / Bears say

Third-quarter revenue rose 29% to $1.3 billion, and Moderna lifted its 2026 revenue-growth forecast to 15%–25%. Stronger international COVID vaccine sales and government partnerships are helping support the recovery. (SEC)
In a Phase 3 melanoma trial, intismeran plus Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. The result gives Moderna a potentially valuable oncology product, although regulatory approval is still ahead. (Moderna)
The FDA approved mFLUSIVA for adults aged 50 and over, making it the first approved mRNA seasonal flu vaccine. Its late approval means this season’s US launch is limited, but it adds a new product to Moderna’s respiratory vaccine portfolio. (Reuters)
Moderna remains heavily reliant on COVID vaccines: they generated $1.68 billion of its $1.72 billion in product sales in the first nine months of 2026. That leaves the business exposed if COVID vaccine demand weakens before newer products contribute meaningfully. (SEC)
The company used $2.7 billion of operating cash in the first nine months of 2026, and expects annual cash costs of $4 billion to $4.5 billion through 2030. Convertible-note financing has bolstered liquidity, but adds debt and possible dilution while substantial spending continues. (Yahoo Finance)
Moderna’s Phase 3 norovirus vaccine trial did not meet the criteria for early success, and the company is not adding another cohort this season while it consults regulators. The delay leaves the programme’s path forward uncertain. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 18 Nov 2026.

Moderna Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Moderna Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Moderna

AllUSDEURGBP
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.